Matisse Pharmaceuticals is a biopharmaceutical company developing therapies for sepsis and septic shock by targeting cytotoxic histones.
Matisse Pharmaceuticals has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Matisse Pharmaceuticals's investors include Brightlands Venture Partners, Chemelot Ventures, LIOF, Limburg Business Development Fund (LBDF).
Matisse Pharmaceuticals is headquartered in Geleen, The Netherlands.
Matisse Pharmaceuticals is a biopharmaceutical company developing therapies for sepsis and septic shock by targeting cytotoxic histones.
Matisse Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Matisse Pharmaceuticals — Funding & Investors." VCBacked, September 17, 2026, https://www.vcbacked.co/company/matisse-pharmaceuticals. Accessed October 3, 2026.
VCBacked. (2026). Matisse Pharmaceuticals — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/matisse-pharmaceuticals
{{cite web |title=Matisse Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/matisse-pharmaceuticals |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated